Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 27, 2025
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated January 27, 2025. The document serves to update the registration statements on Form F-3 and Form S-8. The provided text contains only the cover page, incorporation by reference language, exhibit index, and signatures; it does not include the full text of the press release or specific operational details.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide data to compare against prior periods. No material changes regarding financial performance or operations can be summarized from the cover page alone.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, risk factors, or details on contingencies. The content is limited to the administrative incorporation of a press release into existing registration statements.
Investor Verification Checklist
- Review Exhibit 99.1: The core information regarding the company's status is contained in the press release dated January 27, 2025, which is referenced but not included in the provided text.
- Check Registration Statements: Verify the impact of this filing on the active Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) registration statements.
- Confirm Clinical Updates: As Innate Pharma is a biopharmaceutical company, investors should verify if the press release contains updates on clinical trials, regulatory approvals, or partnership agreements.